Regenstrief, Indiana U offer new IT grad programs

In collaboration with the biomedical and public health informatics research foundation Regenstrief Institute, the Indiana University School of Informatics in Indianapolis will create specialized one- and two-year graduate programs to address the health IT workforce needs.

While a growing number of hospitals and physicians want to offer their patients the benefits of EMRs and health information exchanges, there is a nationwide shortage of health IT workers to fill an estimated 60,000 positions, according to the university.

The new programs are supported by a $1.4 million competitively awarded training grant from the Office of the National Coordinator for Health IT (ONC) as part of a $118 million effort by ONC to increase the availability of skilled health IT professionals.

Offering a combination of classroom instruction, distance accessible learning opportunities and on-the-job training, training programs include:
  • Clinician leader (one-year training program);
  • Public health leader (one-year training program);
  • Health information management and exchange specialist (one-year training program);
  • Health information privacy and security specialist (one-year training program);
  • Programmer and software engineer (one-year training program); and
  • Research and development scientist (two-year master's degree).

Tuition support is available for the most qualified applicants, the university stated. More information on the programs can be found on the university's web site.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.